机构：[a]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China,研究所北京市神经外科研究所首都医科大学附属天坛医院[b]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China,重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[c]China National Clinical Research Center for Neurological Diseases, Beijing, China,[d]Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Background: Gliomas are aggressive tumors with various molecular and clinical characteristics and exhibit strongly resistance to radio-chemotherapy. Programmed cell death 1 ligand 2 (PD-L2) is a cell surface protein, which was reported in many cancers, modulating cancer-associated immune responses, while the role of PD-L2 in gliomas remained unclear. Herein, we aimed to investigate the biological behaviors and clinical prognostic values of PD-L2 in gliomas. Methods: Totally, we enrolled RNA sequencing data of 325 glioma samples from Chinese Glioma Genome Atlas (CGGA) as training cohort and RNA expression data of 1032 samples from The Cancer Genome Atlas (TCGA) dataset as validation cohort in this research. Then, the clinical and molecular characteristics, and the prognostic value of PD-L2 were analyzed. Results: We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma. Receiver Operating Characteristic (ROC) analysis revealed that PD-L2 was a potential indicator of mesenchymal subtype. PD-L2 exhibited tight relationship with immune response and immune-modulating process in glioma. Moreover, PD-L2 expression level could predict unfavorable prognoses of patients independent of age, grade, IDH status and 1p/19q status. Conclusions: Our study revealed that PD-L2 was closely related with inflammation and immune response. Patients with lower PD-L2 expression level tended to experience improved survival. Targeting PD-L2 may become a valuable approach for the treatment of gliomas in clinical practice.
基金：
National Key Research and Development Plan [2016YFC0902500]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81761168038]; Capital Medical Development Research Fund [2016-1-1072]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special [ZYLX201708]
第一作者机构：[a]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China,
通讯作者：
通讯机构：[a]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China,[b]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China,[c]China National Clinical Research Center for Neurological Diseases, Beijing, China,[d]Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China[*1]Beijing Neurosurgical Institute, Capital Medical University, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.6 TiantanXili, Dongcheng District, Beijing 100050, China[*2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.6 TiantanXili, Dongcheng District, Beijing 100050, China[*3]Beijing Neurosurgical Institute, Capital Medical University, No.6 TiantanXili, Dongcheng District, Beijing 100050, China.
推荐引用方式(GB/T 7714)：
Zhi-liang Wang,Guan-zhang Li,Qiang-wei Wang,et al.PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor[J].ONCOIMMUNOLOGY.2019,8(2):-.doi:10.1080/2162402X.2018.1541535.
APA：
Zhi-liang Wang,Guan-zhang Li,Qiang-wei Wang,Zhao-shi Bao,Zheng Wang...&Tao Jiang.(2019).PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.ONCOIMMUNOLOGY,8,(2)
MLA：
Zhi-liang Wang,et al."PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor".ONCOIMMUNOLOGY 8..2(2019):-
医学